{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:00:53Z","timestamp":1790834453260,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.pbb.2022.173490","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T02:13:41Z","timestamp":1668219221000},"page":"173490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The \u03b12C-adrenoceptor antagonist JP-1302 controls behavioral parameters, tyrosine hydroxylase activity and receptor expression in a rat model of ketamine-induced schizophrenia-like deficits"],"prefix":"10.1016","volume":"221","author":[{"given":"Nurdan","family":"Tekin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011fba Eryi\u011fit","family":"Karamahmuto\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asl\u0131","family":"Ayka\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Akak\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Zafer","family":"G\u00f6ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2022.173490_bb0005","first-page":"14","article-title":"Is the acute NMDA receptor hypofunction a valid model of schizophrenia?","volume":"9","author":"Adell","year":"2012","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.pbb.2022.173490_bb0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10339-011-0430-z","article-title":"The novel object recognition memory: neurobiology, test procedure, and its modifications","volume":"13","author":"Antunes","year":"2012","journal-title":"Cogn. Process."},{"issue":"5","key":"10.1016\/j.pbb.2022.173490_bb0015","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.neuropharm.2009.01.021","article-title":"GABAB\/NMDA receptor interaction in the regulation of extracellular dopamine levels in rodent prefrontal cortex and striatum","volume":"56","author":"Balla","year":"2009","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.pbb.2022.173490_bb0020","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.pnpbp.2004.06.019","article-title":"Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity","volume":"28","author":"Becker","year":"2004","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.pbb.2022.173490_bb0025","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0278-5846(03)00080-0","article-title":"Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia","volume":"27","author":"Becker","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pbb.2022.173490_bb0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0306-4522(99)00428-5","article-title":"Overexpression of alpha2C-adrenoceptors impairs water maze navigation","volume":"95","author":"Bj\u00f6rklund","year":"2000","journal-title":"Neuroscience"},{"issue":"8","key":"10.1016\/j.pbb.2022.173490_bb0045","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.neuropharm.2004.02.008","article-title":"SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats","volume":"46","author":"Boulay","year":"2004","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.pbb.2022.173490_bb0055","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0306-4522(01)00531-0","article-title":"Two \u03b12-adrenergic receptor subtypes, \u03b12A and \u03b12C, inhibit transmitter release in the brain of gene-targeted mice","volume":"109","author":"B\u00fccheler","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2022.173490_bb0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jpsychires.2016.06.013","article-title":"Effect of folic acid on oxidative stress and behavioral changes in the animal model of schizophrenia induced by ketamine","volume":"81","author":"Calixto","year":"2016","journal-title":"J. Psychiatr. Res."},{"issue":"3","key":"10.1016\/j.pbb.2022.173490_bb0065","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/0306-4522(89)90012-2","article-title":"Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats","volume":"28","author":"Carboni","year":"1989","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2022.173490_bb0070","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/archpsyc.1962.01710230063007","volume":"6","author":"Cohen","year":"1962","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2022.173490_bb0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF02246146","article-title":"Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors","volume":"120","author":"Corbett","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173490_bb0080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijdevneu.2019.10.006","article-title":"Effects of ketamine on prepubertal Wistar rats: implications on behavioral parameters for childhood-onset schizophrenia","volume":"79","author":"Damazio Pacheco","year":"2019","journal-title":"Int. J. Dev. Neurosci."},{"issue":"1","key":"10.1016\/j.pbb.2022.173490_bb0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11011-011-9234-1","article-title":"Behavioral changes and mitochondrial dysfunction in a rat model of schizophrenia induced by ketamine","volume":"26","author":"De Oliveira","year":"2011","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.pbb.2022.173490_bb0090","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.pnpbp.2016.07.002","article-title":"The \u03b12C-adrenoceptor antagonist, ORM-10921, has antipsychotic-like effects in social isolation reared rats and bolsters the response to haloperidol","volume":"71","author":"Dreyer","year":"2016","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pbb.2022.173490_bb0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0014-2999(99)00070-9","article-title":"Locomotion elicited by MK801 in developing and adult rats: temporal, environmental, and gender effects","volume":"369","author":"Frantz","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173490_bb0100","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s11064-007-9357-2","article-title":"Fluoxetine partly exerts its actions through GABA: a neurochemical evidence","volume":"32","author":"G\u00f6ren","year":"2007","journal-title":"Neurochem. Res."},{"issue":"4","key":"10.1016\/j.pbb.2022.173490_bb0105","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.neuroscience.2010.03.032","article-title":"Ketamine impairs recognition memory consolidation and prevents learning-induced increase in hippocampal brain-derived neurotrophic factor levels","volume":"167","author":"Goulart","year":"2010","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.pbb.2022.173490_bb0110","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.biopsych.2004.06.023","article-title":"Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria","volume":"56","author":"Green","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2022.173490_bb0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/46040","article-title":"Two functionally distinct \u03b12-adrenergic receptors regulate sympathetic neurotransmission","volume":"402","author":"Hein","year":"1999","journal-title":"Nature."},{"key":"10.1016\/j.pbb.2022.173490_bb0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neubiorev.2015.10.014","article-title":"Sex differences in animal models of schizophrenia shed light on the underlying pathophysiology","volume":"67","author":"Hill","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pbb.2022.173490_bb0130","series-title":"Handbook of Chemical Neuroanatomy,Vol. 2, Part 1","author":"H\u00f6kfelt","year":"1984"},{"issue":"2","key":"10.1016\/j.pbb.2022.173490_bb0135","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0091-3057(91)90571-I","article-title":"Ketamine-induced hyperlocomotion associated with alteration of presynaptic components of dopamine neurons in the nucleus accumbens of mice","volume":"40","author":"Irifune","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"2","key":"10.1016\/j.pbb.2022.173490_bb0140","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/070674376701200217","article-title":"Effect of phencyclidine in chronic schizophrenics","volume":"12","author":"Itil","year":"1967","journal-title":"Can. Psychiatr. Assoc. J."},{"issue":"10159","key":"10.1016\/j.pbb.2022.173490_bb0145","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"James","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pbb.2022.173490_bb0150","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1476-5381.2011.01386.x","article-title":"Animal models of schizophrenia","volume":"164","author":"Jones","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.pbb.2022.173490_bb0155","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0014-2999(03)01308-6","article-title":"alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs","volume":"462","author":"Kalkman","year":"2003","journal-title":"Eur. J. Pharmacol."},{"issue":"2-3","key":"10.1016\/j.pbb.2022.173490_bb9165","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","article-title":"The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery","volume":"68","author":"Keefe","year":"2004","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.pbb.2022.173490_bb0165","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.pbb.2022.173490_bb0170","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2022.173490_bb0175","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00228-009-0650-7","article-title":"The change in plasma GABA, glutamine and glutamate levels in fluoxetine- Or S-citalopram-treated female patients with major depression","volume":"65","author":"K\u00fc\u00e7\u00fckibrahimo\u011flu","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.pbb.2022.173490_bb0185","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0306-4522(02)00652-8","article-title":"Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268","volume":"117","author":"Lorrain","year":"2003","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.pbb.2022.173490_bb0190","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.pbb.2022.173490_bb0200","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.euroneuro.2019.03.013","article-title":"Sex-dependent changes in ketamine-induced locomotor activity and ketamine pharmacokinetics in preweanling, adolescent, and adult rats","volume":"29","author":"McDougall","year":"2019","journal-title":"Eur. Neuropsychopharm."},{"issue":"8","key":"10.1016\/j.pbb.2022.173490_bb0210","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.pbb.2022.173490_bb0215","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.neuroscience.2008.01.046","article-title":"Stereological estimates of dopaminergic, GABAergic and glutamatergic neurons in the ventral tegmental area, substantia nigra and retrorubral field in the rat","volume":"152","author":"Nair-Roberts","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2022.173490_bb0220","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/0269881113480991","article-title":"The 5-hydroxytryptamine (serotonin) receptor 6 agonist EMD 386088 ameliorates ketamine-induced deficits in attentional set shifting and novel object recognition, but not in the prepulse inhibition in rats","volume":"27","author":"Nikiforuk","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.pbb.2022.173490_bb0230","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/npp.2017.40","article-title":"Improved social interaction, recognition and working memory with cannabidiol treatment in a prenatal infection (poly I:C) Rat Model","volume":"42","author":"Osborne","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2022.173490_bb0235","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00210-020-02001-1","article-title":"Effects of tamoxifen and glutamate and glutamine levels in brain regions in repeated sleep deprivation\u2013induced mania model in mice","volume":"394","author":"\u00d6zakman","year":"2021","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173490_bb0240","series-title":"The Rat Brain: In Stereotaxis Coordinates","author":"Paxinos","year":"2007"},{"issue":"2","key":"10.1016\/j.pbb.2022.173490_bb0245","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.neuroscience.2008.04.001","article-title":"Effects of sub-anesthetic doses of ketamine on rats' spatial and non-spatial recognition memory","volume":"154","author":"Pitsikas","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2022.173490_bb0250","first-page":"1","article-title":"Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer\u2019s disease","volume":"3(1)","author":"Rinne","year":"2016","journal-title":"Alzheimer\u2019s Dementia"},{"issue":"3","key":"10.1016\/j.pbb.2022.173490_bb0255","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1124\/jpet.118.251652","article-title":"Sex differences in the pharmacokinetics of low-dose ketamine in plasma and brain of male and female rats","volume":"367","author":"Saland","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.pbb.2022.173490_bb0260","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/mol.51.1.36","article-title":"Genetic alteration of alpha 2C-adrenoceptor expression in mice: influence on locomotor, hypothermic, and neurochemical effects of dexmedetomidine, a subtype-nonselective alpha 2-adrenoceptor agonist","volume":"51","author":"Sallinen","year":"1997","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2022.173490_bb0265","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/sj.bjp.0707005","article-title":"Pharmacological characterization and CNS effects of a novel highly selective \u03b1 2C-adrenoceptor antagonist JP-1302","volume":"150","author":"Sallinen","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.pbb.2022.173490_bb0270","first-page":"S435","article-title":"ORM-12741: Receptor pharmacology of a novel alpha2c-adrenergic receptor subtype selective antagonist with multi-therapeutic potential. Poster Session III-Wednesday","volume":"38","author":"Sallinen","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pbb.2022.173490_bb0275","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bcpt.12090","article-title":"Pharmacological characterisation of a structurally novel \u03b12C -adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models","volume":"113","author":"Sallinen","year":"2013","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.pbb.2022.173490_bb0280","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00008877-199601000-00001","article-title":"Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia","volume":"7","author":"Sams-Dodd","year":"1996","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173490_bb0285","first-page":"196","article-title":"Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test","volume":"8","author":"Sams-Dodd","year":"1997","journal-title":"Behav. Pharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2022.173490_bb0290","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00213-018-5130-2","article-title":"Selective adrenergic alpha2C receptor antagonist ameliorates acute phencyclidine-induced schizophrenia-like social interaction deficits in rats","volume":"236","author":"Savolainen","year":"2019","journal-title":"Psychopharmacology"},{"issue":"19-20","key":"10.1016\/j.pbb.2022.173490_bb0295","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/S0024-3205(01)01016-5","article-title":"Evaluation of the \u03b1 2C -adrenoceptor as a neuropsychiatric drug target: Studies in transgenic mouse models","volume":"68","author":"Scheinin","year":"2001","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2022.173490_bb0300","article-title":"Antipsychotic drug doses and neuroleptic\/dopamine receptors","volume":"717-719","author":"Seeman","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2022.173490_bb0305","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.059","article-title":"Neural circuit dysfunction in schizophrenia: insights from animal models","volume":"321","author":"Sigurdsson","year":"2016","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.pbb.2022.173490_bb0310","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.neuron.2010.02.014","article-title":"A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia","volume":"65","author":"Simpson","year":"2010","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.pbb.2022.173490_bb9310","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.pbb.2022.173490_bb0315","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bjp.0707007","article-title":"JP-1302: a new tool to shed light on the roles of \u03b1 2C- adrenoceptors in brain","volume":"150","author":"Tricklebank","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173490_bb0320","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fpsyt.2017.00144","article-title":"Therapeutic potential of selectively targeting the \u03b12C -adrenoceptor in cognition, depression, and schizophrenia\u2014New developments and future perspective","volume":"8","author":"Uys","year":"2017","journal-title":"Front. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2022.173490_bb0325","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/FBP.0000000000000261","article-title":"The \u03b12C-adrenoceptor antagonist, ORM-10921, exerts antidepressant-like effects in the Flinders Sensitive Line rat","volume":"28","author":"Uys","year":"2017","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173490_bb0335","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3371\/CSRP.4.2.4","article-title":"Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development","volume":"4","author":"Wilson","year":"2010","journal-title":"Clin. Schizophrenia Relat. Psychoses"},{"issue":"2\u20133","key":"10.1016\/j.pbb.2022.173490_bb0340","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.physbeh.2007.02.010","article-title":"Effects of age and sex on ketamine-induced hyperactivity in rats","volume":"91","author":"Wilson","year":"2007","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.pbb.2022.173490_bb0345","article-title":"Optogenetic induction of the schizophrenia-related endophenotype of ventral hippocampal hyperactivity causes rodent correlates of positive and cognitive symptoms","volume":"8-12871","author":"Wolff","year":"2018","journal-title":"Sci. Report."},{"issue":"2\u20133","key":"10.1016\/j.pbb.2022.173490_bb0350","first-page":"162","article-title":"Effects of omega-3 dietary supplement in prevention of positive, negative and cognitive symptoms: a study in adolescent rats with ketamine-induced model of schizophrenia","volume":"141","author":"Zugno","year":"2012","journal-title":"Schizophr. Res."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722001691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722001691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:46:05Z","timestamp":1758775565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305722001691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":62,"alternative-id":["S0091305722001691"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173490","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The \u03b12C-adrenoceptor antagonist JP-1302 controls behavioral parameters, tyrosine hydroxylase activity and receptor expression in a rat model of ketamine-induced schizophrenia-like deficits","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"173490"}}